Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
因塞特(US:INCY) Businesswire·2026-03-07 05:42核心事件 - 欧洲委员会批准了Zynyz (retifanlimab)用于一线治疗晚期肛管鳞状细胞癌 [1] 公司动态 - 公司Incyte宣布了其产品Zynyz在欧洲获得监管批准的消息 [1] - 获批适应症为一线治疗晚期肛管鳞状细胞癌 [1]